BioSpace News Archive

Following a court’s ruling last week over a partial clinical hold placed on the company in 2018 by the U.S. Food and Drug Administration, Vanda Pharmaceuticals said it is undertaking a “comprehensive review” of the decision and will then determine the next appropriate steps.

“We have successfully engineered a new molecule, which is a modified sugar that shows broad-spectrum antiviral properties,” said Samuel Jones, from The University of Manchester.

The National Institutes of Health ceased administration of an investigational HIV vaccine after interim data revealed that the treatment was not working in preventing the virus.

“Anteros Pharmaceuticals is the first of several companies that BioMotiv and Bristol-Myers Squibb intend to form under the Strategic Partnership Agreement,” said Satish Jindal, BioMotiv’s chief executive officer.

Pattern Bioscience was awarded funding from CARB-X to develop a new rapid diagnostic for drug-resistant bacterial infection.

Your organization needs to figure out how to come up with ideas for cultivating diversity and inclusion in the workplace.

The active component of the drug, sodium valproate, has been on the market for epilepsy and bipolar disorder since 1967.

Asklepios BioPharmaceutical (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, and its NanoCor Therapeutics subsidiary today announced that the first patient has been dosed in a Phase 1 clinical trial of NAN-101. NAN-101 is a gene therapy that aims to activate protein phosphatase inhibitor 1 (I-1c) to inhibit the activity of protein phosphatase 1 (PP1), a substance that plays an important role in the development of heart failure.

Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is scheduled to participate in the BIO CEO & Investor Conference at the New York Marriott Marquis in New York on Feb 10th-11th.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, today announced the publication of a scientific paper entitled, “The Novel Reversible LSD1 Inhibitor SP-2577 Promotes Anti-Tumor Immunity in SWItch/Sucrose-NonFermentable (SWI/SNF)1,” available in preprint at bioRxiv.com.